(VIVS)

NCM – Real Time Price. Currency in USD

1.62

-0.07 (-4.14%)

At close: Mar 27, 2026, 4:00 PM EDT

1.39

-0.23 (-14.50%)

After-hours: Mar 27, 2026, 7:42 PM EDT

Videos

No Data

There is no data to display

Press releases

24.03.2026

VivoSim Releases Antibody Drug Conjugate (ADC) Data Showing Power to Detect ADC Toxicity and Guide Design of Safer ADCs

ADCs are a major new market; Company demonstrates ability to discern antibody toxicity from payload toxicity and show differential linker chemistry toxicity ADCs are a major new market; Company demonstrates ability to discern antibody toxicity from payload toxicity and show differential linker chemistry toxicity

03.03.2026

VivoSim Appoints Arumugham (Ragoo) Raghunathan as Vice President of Global Sales

Veteran business development leader with deep expertise in human-relevant NAM and spheroid-based in vitro services to spearhead commercial growth along the US East Coast, deepening VivoSim's reach with biopharma innovators seeking human-relevant liver and GI toxicity solutions Veteran business development leader with deep expertise in human-relevant NAM and spheroid-based in vitro services to spearhead commercial growth along the US East Coast, deepening VivoSim's reach with biopharma innovators seeking human-relevant liver and GI toxicity solutions

11.02.2026

VivoSim to Debut Antibody Drug Conjugate Data, representing a major new market for NAMkind models, at Society of Toxicology Meeting in San Diego

Company produces thorough reference testing on Antibody Drug Conjugates, showing high correlation with clinical liver and intestinal toxicity and side effects Company produces thorough reference testing on Antibody Drug Conjugates, showing high correlation with clinical liver and intestinal toxicity and side effects

29.01.2026

VivoSim Expands Asia-Pacific Access to NAMKind™ Human-Based Toxicology Services Through New Distributor Agreement in Korea and China

SAN DIEGO, Jan. 29, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the “Company” or “VivoSim Labs”), a provider of next-generation New Approach Methodologies (NAMs) for preclinical safety, today announced it has signed JCBio as an authorized distributor in Korea and Tekon Biotech as an authorized distributor in China for its NAMKind™ toxicology services in liver and small intestine. The appointments expand VivoSim's commercial presence across Asia-Pacific, which potentially provides faster access to human-relevant toxicology services for pharmaceutical and biotechnology organizations facing growing pressure to de-risk programs earlier and accelerate timelines.

(VIVS)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

(VIVS)

Videos

No Data

Press releases

VivoSim Releases Antibody Drug Conjugate (ADC) Data Showing Power to Detect ADC Toxicity and Guide Design of Safer ADCs

VivoSim Appoints Arumugham (Ragoo) Raghunathan as Vice President of Global Sales

VivoSim to Debut Antibody Drug Conjugate Data, representing a major new market for NAMkind models, at Society of Toxicology Meeting in San Diego

VivoSim Expands Asia-Pacific Access to NAMKind™ Human-Based Toxicology Services Through New Distributor Agreement in Korea and China

Videos

No Data

Press releases

VivoSim Releases Antibody Drug Conjugate (ADC) Data Showing Power to Detect ADC Toxicity and Guide Design of Safer ADCs

VivoSim Appoints Arumugham (Ragoo) Raghunathan as Vice President of Global Sales

VivoSim to Debut Antibody Drug Conjugate Data, representing a major new market for NAMkind models, at Society of Toxicology Meeting in San Diego

VivoSim Expands Asia-Pacific Access to NAMKind™ Human-Based Toxicology Services Through New Distributor Agreement in Korea and China